Primer group and kit for detecting SNP (Single Nucleotide Polymorphism) sites related to venous thromboembolism
Through the SNP site detection primer set and kits related to venous thromboembolic disease, combined with nucleic acid mass spectrometry, the problem that the existing technology cannot meet the multi-gene multi-site detection needs is solved, and rapid, economical and accurate detection is achieved, suitable for Batch inspection reduces costs and cycles.
Patent Information
- Application Number
- CN202411320277.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-20
- Publication Date
- 2024-11-29
AI Technical Summary
The existing technology cannot meet the clinical needs of multiple genes and multi-locus venous thromboembolic disease detection, and cannot achieve economical, fast and easy-to-operate detection methods. It also has high cost, long cycle and high technical requirements. , not popularized.
Provides primer sets and kits for detecting SNP sites related to venous thromboembolic disease. Combined with nucleic acid mass spectrometry, it can quickly detect SNP sites related to venous thromboembolic disease, realize multi-gene loci detection, and reduce detection costs and cycles.
Accurate detection of 27 SNP sites of 9 genes related to venous thromboembolic disease has been achieved, which shortens the detection cycle and improves the detection efficiency, is suitable for batch testing, reduces costs, and provides a reference for the assessment of genetic risk of venous thromboembolic disease. .
Smart Images

Figure CN119040453A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of venous thromboembolism detection, and in particular to a primer set and a kit for detecting SNP sites related to venous thromboembolism. Background Art
[0002] Venous thromboembolism (VTE) is a venous reflux disorder caused by abnormal coagulation of blood in the deep veins. It often occurs in the lower limbs and is the third most common vascular disease after ischemic heart disease and stroke. It mainly manifests as deep vein thrombosis (DVT) and pulmonary embolism (PTE), which are two forms of manifestations at different stages and different parts. Clinically, about 80% of DVT patients have no obvious symptoms, and sudden death is often the first symptom. Therefore, it is called the "silent killer." VTE is a complex multi-gene-environmental factor disease. About 60% of the differences in individual susceptibility to VTE are attributed to genetic factors. Genetic factors determine the susceptibility of different individuals to VTE, and this susceptibility accompanies lifelong.
[0003] In order to improve the standardized prevention rate of VTE, achieve early intervention of VTE, effectively reduce the incidence and mortality of VTE, and reduce doctor-patient conflicts and medical disputes, the National Health Commission has successively issued a number of documents and made the prevention and treatment of VTE a key element and goal of medical quality management.
[0004] At present, there are many detection methods with their own characteristics. PCR-based detection methods, such as ARMS-PCR, fluorescent quantitative PCR, digital PCR, etc., are easy to operate, fast, and simple to analyze data. However, due to the limitation of throughput, they cannot meet the clinical needs for multiple genes and multiple sites detection. High-throughput gene detection technology, such as high-throughput sequencing technology, solves the limitation of throughput, but it is costly, has a long detection cycle, and has high technical requirements for experimental operators and data analysts. Therefore, it has not yet been widely used in clinical detection.
[0005] In summary, there is an urgent need for an economical, rapid, and easy-to-use detection method that can assess the genetic risk of VTE by detecting anticoagulant function defects, hypercoagulant function, hyperfibrinolytic function, and metabolic defect genes, which will help to identify high-risk groups early, prevent them early, avoid or delay disease progression, and achieve early detection, early prevention, and early treatment. It can also guide clinicians to determine appropriate thrombosis prevention and treatment plans for different patients, avoid the occurrence of fatal pulmonary embolism and deep vein thrombosis, and reduce the risk of perioperative death. Summary of the invention
[0006] The present invention provides a primer set and a kit for detecting SNP sites associated with venous thromboembolism. The primer set can be used for specific detection of site mutations associated with venous thromboembolism, and can achieve rapid detection of SNP sites associated with venous thromboembolism based on nucleic acid mass spectrometry, so as to further evaluate the genetic risk of VTE.
[0007] In view of this, the scheme of the present invention is:
[0008] The first aspect of the present invention provides a primer set for detecting SNP sites associated with venous thromboembolism, comprising a first primer set and / or a second primer set; the first primer set comprises a PCR amplification primer pair having a nucleotide sequence as shown in SEQ ID NO: 1-26, and the second primer set comprises a PCR amplification primer pair having a nucleotide sequence as shown in SEQ ID NO: 27-54.
[0009] Furthermore, the first primer set further includes a single base extension primer set having a nucleotide sequence as shown in SEQ ID NOs: 55-67, and the second primer set further includes a single base extension primer set having a nucleotide sequence as shown in SEQ ID NOs: 68-81.
[0010] The second aspect of the present invention provides the use of the primer set described in the first aspect in preparing a product for detecting SNP sites associated with venous thromboembolism.
[0011] The third aspect of the present invention is a venous thromboembolism-related SNP site detection kit based on a nucleic acid mass spectrometry platform, comprising a first primer set and / or a second primer set; the first primer set comprises a PCR amplification primer pair having a nucleotide sequence as shown in SEQ ID NO: 1-26, and a single base extension primer set having a nucleotide sequence as shown in SEQ ID NO: 55-67; the second primer set comprises a PCR amplification primer pair having a nucleotide sequence as shown in SEQ ID NO: 27-54, and a single base extension primer set having a nucleotide sequence as shown in SEQ ID NO: 68-81.
[0012] Furthermore, the kit also includes one or more of a PCR reaction reagent, a SAP reaction reagent and a single base extension reaction reagent.
[0013] Preferably, the multiplex PCR reaction reagents include PCR reaction buffer, Mg 2+ , dNTPs, DNA polymerase, and one or more of water; SAP reaction is a shrimp alkaline phosphatase digestion reaction, and the reagents include SAP reaction buffer, SAP enzyme, and one or more of water; single base extension reaction reagents include single base extension reaction buffer, single base extension reaction termination solution, single base extension reaction enzyme, and one or more of water.
[0014] The fourth aspect of the present invention proposes a venous thromboembolism-related SNP site detection reaction system based on a nucleic acid mass spectrometry platform, comprising a PCR amplification reaction system and a single base extension reaction system; the PCR amplification reaction system contains a first primer group and / or a second primer group; the first primer group includes a PCR amplification primer pair with a nucleotide sequence as shown in SEQ ID NO: 1-26, and the second primer group includes a PCR amplification primer pair with a nucleotide sequence as shown in SEQ ID NO: 27-54; the single base extension reaction system contains a single base extension primer group, which is used to detect the same site as the amplification primer pair in the PCR amplification reaction system.
[0015] Furthermore, the single-base extension primer set includes a first single-base extension primer set having a nucleotide sequence as shown in SEQ ID NOs: 55-67, and / or a second single-base extension primer set having a nucleotide sequence as shown in SEQ ID NOs: 68-81.
[0016] Furthermore, the reaction system also includes one or more of a PCR reaction reagent, a SAP reaction reagent and a single base extension reaction reagent.
[0017] Preferably, the multiplex PCR reaction reagents include PCR reaction buffer, Mg 2+ , dNTPs, DNA polymerase, and one or more of water; SAP reaction is a shrimp alkaline phosphatase digestion reaction, and the reagents include SAP reaction buffer, SAP enzyme, and one or more of water; single base extension reaction reagents include single base extension reaction buffer, single base extension reaction termination solution, single base extension reaction enzyme, and one or more of water.
[0018] Furthermore, in the PCR amplification reaction system, the concentration of each PCR amplification primer with a nucleotide sequence as shown in SEQ ID NO: 1-17 is 0.5 μM.
[0019] Further, the concentration of each primer in the first single-base extension primer set whose nucleotide sequences are shown in SEQ ID NOs: 55-67 is 5.5 μM, 5.5 μM, 8.5 μM, 6.5 μM, 12 μM, 7.5 μM, 10.5 μM, 9 μM, 12 μM, 9.5 μM, 10 μM, 10.5 μM, and 10.5 μM, respectively; the concentration of each primer in the second single-base extension primer set whose nucleotide sequences are shown in SEQ ID NOs: 68-81 is 6 μM, 37 μM, 12.5 μM, 10 μM, 6 μM, 8 μM, 8.5 μM, 9 μM, 9 μM, 9.5 μM, 9.5 μM, 10 μM, 7.5 μM, and 10.5 μM, respectively.
[0020] The fifth aspect of the present invention provides a venous thromboembolism-related SNP site detection system based on a nucleic acid mass spectrometry platform, characterized in that it includes the reaction system described in the fourth aspect, a desalting resin and a spotting chip.
[0021] Compared with the prior art, the present invention has at least the following beneficial effects:
[0022] The kit described in the present invention can detect 27 SNP sites of 9 genes related to venous thromboembolism, has high accuracy and sensitivity, can greatly shorten the detection cycle, and reduce the detection cost; it can realize the detection of multiple gene sites on a single platform, and provide a reference for the genetic risk assessment of venous thromboembolism.
[0023] The kit of the present invention is combined with a nucleic acid mass spectrometry platform for detection, which can realize a detection method for multiple gene sites using a single platform, greatly improving the detection efficiency, and is particularly suitable for batch detection. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 The Typer software cluster diagram of the rs1799762 site provided in the embodiment of the present invention;
[0025] Figure 2 The Typer software cluster diagram of the rs1801133 site provided in the embodiment of the present invention;
[0026] Figure 3 The UEP peak diagram before optimization of the rs199469469 site provided in the optimization case 1 of the present invention;
[0027] Figure 4 The optimized UEP peak diagram of the rs199469469 site provided in the optimization case 1 of the present invention;
[0028] Figure 5 The site peak diagram before optimization of the rs1799762 site provided in the optimization case 1 of the present invention;
[0029] Figure 6 The optimized site peak diagram of the rs1799762 site provided in the optimization case 1 of the present invention;
[0030] Figure 7 The site peak diagram before optimization of the rs121909567 site provided in the optimization case 3 of the present invention;
[0031] Figure 8 The optimized site peak diagram of the rs121909567 site provided in the optimization case 3 of the present invention;
[0032] Fig. 9Peak diagram of reaction well 1 before optimization of VTE-UEP primers provided in optimization case 4 of the present invention;
[0033] Fig.10 Peak diagram of reaction well 2 before optimization of VTE-UEP primers provided in optimization case 4 of the present invention;
[0034] Fig.11 Peak diagram of reaction well 1 after optimization of VTE-UEP primers provided in optimization case 4 of the present invention;
[0035] Fig.12 Peak diagram of reaction well 2 after optimization of VTE-UEP primers provided in optimization case 4 of the present invention;
[0036] Fig.13 This is the cluster diagram of bioinformatics analysis of the rs146922325 locus provided for optimization case 5 of the present invention. DETAILED DESCRIPTION
[0037] The technical solution of the present invention will be clearly and completely described below in conjunction with the preferred embodiments. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0038] In one embodiment, a primer set for detecting SNP sites related to venous thromboembolism is proposed, which is designed for the main mutation sites related to venous thromboembolism, and can achieve specific detection of site mutations related to venous thromboembolism with high accuracy. The detection results cover 27 mutation sites of PROC, PROS1, SERPINC1, F2, F5, HRG, THBD, PAI-1 and MTHFR genes, which can greatly shorten the detection cycle and reduce the detection cost; and realize the detection of multiple gene sites on a single platform, providing a reference for the genetic risk assessment of venous thromboembolism. In addition, the primer set provided is obtained by modification optimization and large sample test screening. All primer sequences can accurately type samples, and can also meet the requirements of mass spectrometry detection technology, realizing the application of MassARRAY platform for rapid and effective detection of venous thromboembolism.
[0039] In a specific embodiment, the SNP sites corresponding to venous thromboembolism include: rs146922325, rs199469469, rs773327173, rs757583846, rs121918153, rs199469503, rs1241365457, rs5017717, rs387906675, rs121918474, rs387906674, rs12190956 2. rs121909554, rs121909551, rs121909546, rs121909547, rs121909567, rs121918486, rs1799963, rs6025, rs201790842, rs118203907, rs761776963, rs121918122, rs398122807, rs1799762, rs1801133. The corresponding designed primers are shown in Table 6.
[0040] It is understandable that the primer pair described in the present invention is a PCR primer pair. In a preferred embodiment, when an extension primer is required for practical application, the primer set further includes 27 extension primers, as shown in Table 7.
[0041] It is understood that the primer pairs and extension primers in the present invention correspond one to one, and the corresponding primer pairs and extension primers are used to detect the nucleotides at the same site. For example, the first primer pair includes an upstream primer of the nucleotide sequence shown in SEQ ID NO: 1, a downstream primer of the nucleotide sequence shown in SEQ ID NO: 2, and an extension primer of the nucleotide sequence shown in SEQ ID NO: 55, and the above primers are all used to detect the nucleotides at the same site.
[0042] Further, the genotypes of each site are listed, as shown in the following table:
[0043]
[0044]
[0045] In an embodiment of the present invention, the venous thromboembolism gene detection is performed by detecting human PROC, PROS1, SERPINC1, F2, F5, HRG, THBD, PAI-1 and MTHFR genes through gene detection technology to discover the genetic risk of venous thromboembolism in different individuals.
[0046] Specifically, the correspondence between the detection sites and the types of diseases is shown in the following table:
[0047]
[0048]
[0049] It should be clarified that the above-mentioned PCR amplification primers and single-base extension reaction primers take into account the size of the extension primers to ensure that there is no interference between the primers in the group.
[0050] In a preferred embodiment, the primer set is divided into two groups, and the grouping takes into account the size of the extension primers to ensure that the primers in each group do not interfere with each other. Specifically:
[0051] The first group includes primer sets for detecting rs199469469, rs121909547, rs121909554, rs121918153, rs773327173, rs121909551, rs146922325, rs121918486, rs761776963, rs121918122, rs201790842, rs121909546, and rs1241365457;
[0052] The second group includes primer sets for detecting rs1799963, rs121918474, rs387906675, rs1799762, rs5017717, rs6025, rs1801133, rs199469503, rs121909562, rs757583846, rs387906674, rs398122807, rs118203907, and rs121909567.
[0053] Specifically, the grouping is carried out in the following manner: the target SNP positioning and the adjacent target SNP are merged, and the relevant parameters are adjusted using a professional website (https: / / www.ncbi.nlm.nih.gov / ) to complete the first round of primer screening. Confirmation of the PCR reaction system: For the initial screening PCR primers, the primer specificity is confirmed by comparing the NCBI database. For sites where specificity is at risk, the primers of the single site are redesigned, and the redesigned primers must ensure specificity in the multiple reaction system. Then a preliminary experiment is performed and the site optimization is completed based on the analysis of the reasons for the detection results. Confirmation of the single-base extension reaction system: For the initial screening UEP primers, the molecular weight between the UEP primers and the extension primers needs to be ≥16Da. The multiple primer ratios are confirmed and adjusted to the optimal solution, and then a preliminary experiment is performed and the site is further optimized based on the analysis of the reasons for the detection results. This product is optimized by the multiple PCR primers, the single-base extension primer sequence, and the single-base extension direction adjustment, and finally determines the two primer sets in the present invention.
[0054] In the above embodiment, MassARRAY gene analysis technology is based on MALDT-TOF time-of-flight mass spectrometry technology, which first amplifies the target sequence by PCR, and then adds SNP sequence-specific extension primers as needed to extend a single base at the SNP site. This technology uses the high sensitivity of mass spectrometry to mass, and can effectively distinguish two gene sequences with only one different base, and then infer the SNP typing.
[0055] In a preferred embodiment of the present invention, the MassARRAY system is used for detection, which realizes a method for detecting multiple gene loci using a single platform, greatly improves the detection efficiency, and is particularly suitable for batch detection.
[0056] In a preferred embodiment, the method further comprises the step of dephosphorylating the PCR product before the base extension reaction. Specifically, the PCR product is dephosphorylated using shrimp alkaline phosphatase.
[0057] In a preferred embodiment, the method further includes a step of purifying the reaction product after the base extension reaction, and then applying MassARRAY to detect the reaction product. Specifically, the reaction product can be purified by resin salt removal, and then spotted onto a chip with a matrix through an instrument to form a co-crystal with the matrix, and then the composite crystal is irradiated with a laser, and the irradiated matrix molecules absorb and accumulate energy and then rapidly heat up, so that the crystal sublimates into a gas phase, and the nucleic acid molecules are also desorbed and transformed into metastable ions (mostly single-charged ions); these single positively charged ions can obtain kinetic energy in the accelerating electric field, and fly toward the detector after flying through the free drift zone, and the smaller the ion mass, the faster the flight speed, and the earlier it arrives at the detector, and nucleic acid molecules of different molecular weights are detected due to different arrival times at the detector.
[0058] The following are preferred embodiments for verifying the technical solution and technical effects of the present invention. Unless otherwise specified, the operations involved are basic means mastered by those skilled in the art.
[0059] The main reagent information used in the following examples is shown in Table 1.
[0060] Table 1: Main reagents
[0061]
[0062]
[0063] The main instrument information used in the following examples is shown in Table 2.
[0064] Table 2: Main instruments
[0065]
[0066] Example 1 Primer design and reaction system establishment
[0067] Through the primer design software (Assay Design Suite) on the MassARRAY website, adjust the relevant parameters, complete the primer design of PCR and UEP for 27 sites, export the designed primers and parameter files, and synthesize primers. Prepare amplification primer MIX and extension primer MIX according to the primer configuration table, and fine-tune the extension primer MIX until it meets the requirements. Then perform primer testing and optimization. The specific steps are as follows:
[0068] (1) Dilute the genomic DNA sample to 10 ng / μL and prepare the PCR reaction MIX according to Table 3 (the following is the amount of a single sample).
[0069] Table 3: PCR reaction system
[0070]
[0071] Seal the film, centrifuge at 2272 g for 1 minute, and place the plate in a PCR instrument for the following thermal cycles:
[0072]
[0073] (2) Shrimp alkaline phosphatase digestion (SAP)
[0074] The PCR plate was removed and centrifuged at 2272 g for 1 minute. The SAP reaction system was prepared according to Table 4 (the following is the amount of a single sample).
[0075] Table 4: SAP reaction system
[0076]
[0077] Add 2 μL of SAP mixture to each reaction well, seal the film, centrifuge at 2272 g for 1 minute, and place the plate on a PCR instrument for the following thermal cycles:
[0078] Temperature(℃) time 37℃ 40min 85℃ 5min 12℃ ∞
[0079] (3) Single base extension (EXT)
[0080] Remove the PCR plate, centrifuge at 2272g for 1 minute, and prepare the EXT reaction system according to Table 5, where Extend PrimerMix is a mixture of extension primers with different sites (the following is the amount of a single sample):
[0081] Table 5: EXT reaction system
[0082]
[0083] Add 2 μL of extension mixture to each reaction well, seal the membrane, centrifuge at 2272 g for 1 minute, and place the plate on a PCR machine for the following thermal cycles:
[0084]
[0085] (4) Resin desalination
[0086] ① Spread the clean resin on the dimpleplate holes and let it air dry for at least 10 minutes;
[0087] ②Take out the sample plate and centrifuge it at 2272g for 1 minute;
[0088] ③ Add 16 μL of water to each well of the sample plate and seal the plate;
[0089] ④ Centrifuge at 2272g for 1 minute and prepare for loading.
[0090] (5) Dispensing
[0091] Use MassARRAY CPM to spot samples onto the corresponding SpectroCHIP (chip).
[0092] (6) MALDI-TOF
[0093] Data were acquired using a MALDI-TOF (matrix-assisted laser desorption ionization-time of flight) mass spectrometer.
[0094] For the optimal PCR amplification primers and single base extension (UEP) primers, see the primer sequences in Tables 6 and 7 for specific primer sequences.
[0095] Table 6: PCR primer sequences
[0096]
[0097]
[0098]
[0099] Table 7: UEP primer sequences
[0100]
[0101]
[0102] Example 2 Verification of the reaction system
[0103] After confirming the optimal reaction system, the present invention conducted a series of verification experiments, including accuracy, precision and comparison experiments between personnel. The specific verification scheme is as follows:
[0104] (1) Accuracy experimental verification plan: 27 detection sites were verified, including rs1799762 and rs1801133 sites, with reference to known results, and another 25 sites with reference to the first generation verification results of plasmids. A total of 53 samples (including 50 gDNA and 3 plasmids) were verified, and the reference results were compared with the results of MassARRAY. The verification was passed when the accuracy consistency was greater than 95%.
[0105] Since the mutation frequencies of anticoagulant factor genes (PROC, PROS1, SERPINC1), coagulation factor genes (F2, F5), and anticoagulant protein deficiency genes (HRG, THBD) in venous thromboembolism genes are low in Asian populations and clinical sample collection is extremely difficult, two types of plasmids, wild-type and mutant, were synthesized, including the following sites: rs199469469, rs121909547, rs121909554, rs121918153, rs773327173, rs121909551, rs146922325, r s121918486, rs761776963, rs121918122, rs201790842, rs121909546, rs1241365457, rs1799963, rs121918474, rs387906675, rs5017717, rs6025, rs199469503, rs121909562, rs757583846, rs387906674, rs398122807, rs118203907 and rs121909567. Fish sperm DNA was mixed with two types of plasmids, and the three mixed plasmid samples were compared and verified (plasmid synthesis was verified by Sanger sequencing).
[0106] (2) Precision test verification plan: Select 3 gDNA samples, and have Experimenter A repeat the first batch of tests for each sample 3 times, Experimenter A repeat the second batch of tests for each sample once, and Experimenter B repeat the third batch of tests for each sample once. Compare the consistency of the results of the 5 repetitions of the 3 samples. The verification is passed if the consistency of inter-batch precision, intra-batch precision, and inter-personnel precision is greater than 95%.
[0107] The specific verification process is as follows: first, according to the system and operation steps provided in Example 1 of the present invention, PCR amplification, shrimp alkaline phosphatase consumption, single base extension, resin desalting and MassARRAY CPM spot analysis were performed respectively, and then the results were analyzed. The accuracy and precision results are shown in Tables 8-9 and 10. Since the results of the precision experiment within and between batches are consistent, only the test results of 3 samples are listed.
[0108] Table 8: Original validation results for accuracy1
[0109]
[0110]
[0111] Note: * Reference item is Sanger
[0112] Table 9: Verification results of accuracy 2
[0113]
[0114]
[0115] Comparison of the MassARRAY results of 50 samples and 3 mixed plasmids with the reference results showed that the accuracy of the system verification experiment of the present invention was 100%.
[0116] Table 10: Precision verification results
[0117]
[0118]
[0119] By comparing the test results of 5 repetitions of 3 gDNA samples, it can be seen that the inter-batch precision, intra-batch precision, and consistency of the comparison between personnel and between reagents of the system of the present invention are all 100%.
[0120] Since the present invention detects many sites, two sites rs1799762 and rs1801133, which contain three types of homozygous wild type, homozygous mutant type and heterozygous mutant type, are selected for display. The Typer software clustering diagrams of the above two sites are as follows: Figure 1 and Figure 2 .
[0121] Optimization case 1: Taking the optimization of rs199469469 site as an example (adjustment of extension primers)
[0122] The genotypes detected at the rs199469469 site are AAG / AAG, AAG / DEL, and DEL / DEL. If the design of the reverse UEP primer AAG and DEL extension bases are both G, the two genotypes cannot be distinguished, that is, the extension primer can only be designed in the forward direction. The rs199469469 site and the rs146922325 site are adjacent sites. The rs199469469 site is 11bp after the rs146922325 site. If the forward UEP primer of the rs199469469 site is designed, it will definitely cross the rs146922325 site. The genotypes detected at the rs146922325 site are CC, TT, and CT. The original design of the UEP primer sequence for the rs199469469 site is AGyGGATGGAGAAG. The primer contains a degenerate base that can bind to the two genotypes of the rs146922325 site, but the UEP peak is a double peak and cannot be used. Figure 3 Gu chose to change the UEP primer sequence from AGyGGATGGAGAAG to AGAGGATGGAGAAG, and the base was modified to base A, which did not bind to any genotype of the rs146922325 site. It was found that the UEP primer could be detected normally after the change. Figure 4 This indicates that the primers after the change are better than the primers before the change and meet the detection requirements.
[0123] Optimization case 2: Taking the optimization of rs1799762 site as an example (adjustment of extension primers)
[0124] The rs1799762 locus is fixed to detect the genotype DEL, such as Figure 5 . Software analysis found that the rs1799762 site extension primer and the rs121918486 site in the same detection well had a medium extension dimer potential (0.452). Gu chose to change the direction of the UEP primer, and the UEP primer sequence was changed from GAGTCTGGACACGTGGGG to CACGGCTGACTCCCC. After the change, the test was performed according to the above steps. The genotype detected at the rs1799762 site was consistent with the theoretical result. Figure 6 This indicates that the primers after the change are better than the primers before the change and meet the detection requirements.
[0125] Optimization case 3: Taking the optimization of rs121909567 site as an example (adjustment of extension primers)
[0126] The molecular weight of the extension peak A of the rs121909567 site is too close to that of the UEP primer peak of the rs121909551 site, which affects the interpretation of the results of the rs121909567 site. Figure 7Gu selected and optimized the UEP primer sequence of rs121909567, changing it from GTGCCTGTAATGACACC to TGTTCGTACCTCCATCAGTTGCTGGA. And distributed the rs121909567 site and rs121909551 site in VTE reaction 2 and VTE reaction 1, respectively. Figure 8 After optimization, there was no mutual interference between the two sites, which met the detection requirements.
[0127] Optimization case 4: Taking the optimization of the ratio of the VTE-UEP primer system as an example
[0128] After the optimization of the single-site primers in the detection system of the present invention is completed, it is necessary to optimize the multiple primer ratios to ensure that the detection of each site will not affect each other and the peak height of each site is relatively uniform. Gu selected and optimized the ratio of UEP primers in each detection system, and the lowest peak in the reaction well needs to be higher than 1 / 2 of the highest peak. The specific optimization ratio is shown in Table 11. The peak diagram of UEP primers before optimization is as follows Fig. 9 , Fig.10 The peak diagram of optimized UEP primers is as follows: Fig.11 , Fig.12 .
[0129] Table 11: VTE-UEP primer ratio optimization
[0130]
[0131]
[0132] Optimization case 5: Taking the threshold construction of the system of the present invention as an example
[0133] The performance verification accuracy data and reference result data of the present invention are compared, and the analysis threshold is constructed by cluster analysis method. The homozygous interval, heterozygous interval and gray area interval range are set according to the known results. Further verification, confirmation and optimization adjustment are performed for suspicious or discrete data. The final optimized threshold is used as the bioinformatics analysis threshold of the product of the present invention. This product can directly perform bioinformatics analysis to output test results. The result output process is simple and fast, and no manual interpretation is required, which can greatly improve the experimental efficiency. Taking the rs146922325 site as an example, the analysis threshold is shown in Table 12, and the cluster diagram is shown in Fig.13 shown.
[0134] Table 12: rs146922325 site analysis threshold
[0135] Assay_Id HetMax+sd HetMin-sd HomMax+sd rs146922325 1.0000 0.6117 0.2161
[0136] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A primer set for detecting SNP sites associated with venous thromboembolism, characterized in that: It includes a first primer set and / or a second primer set; the first primer set includes a PCR amplification primer pair with nucleotide sequences as shown in SEQ ID NO: 1-26, and the second primer set includes a PCR amplification primer pair with nucleotide sequences as shown in SEQ ID NO: 27-54.
2. The primer set according to claim 1, characterized in that The first primer set further includes a single base extension primer set with nucleotide sequences as shown in SEQ ID NOs: 55-67, and the second primer set further includes a single base extension primer set with nucleotide sequences as shown in SEQ ID NOs: 68-81.
3. Use of the primer set according to claim 1 or 2 in preparing a product for detecting SNP sites associated with venous thromboembolism.
4. A venous thromboembolism-related SNP site detection kit based on a nucleic acid mass spectrometry platform, characterized in that: It includes a first primer set and / or a second primer set; the first primer set includes a PCR amplification primer pair with nucleotide sequences as shown in SEQ ID NOs: 1-26, and a single base extension primer set with nucleotide sequences as shown in SEQ ID NOs: 55-67; the second primer set includes a PCR amplification primer pair with nucleotide sequences as shown in SEQ ID NOs: 27-54, and a single base extension primer set with nucleotide sequences as shown in SEQ ID NOs: 68-81.
5. The kit according to claim 4, characterized in that The kit further comprises one or more of a PCR reaction reagent, a SAP reaction reagent and a single base extension reaction reagent.
6. A venous thromboembolism-related SNP site detection reaction system based on a nucleic acid mass spectrometry platform, characterized in that: It comprises a PCR amplification reaction system and a single base extension reaction system; the PCR amplification reaction system comprises a first primer set and / or a second primer set; the first primer set comprises a PCR amplification primer pair having a nucleotide sequence as shown in SEQ ID NO: 1-26, and the second primer set comprises a PCR amplification primer pair having a nucleotide sequence as shown in SEQ ID NO: 27-54; the single base extension reaction system comprises a single base extension primer set for detecting the same site as the amplification primer pair in the PCR amplification reaction system.
7. The reaction system according to claim 6, characterized in that The single-base extension primer set includes a first single-base extension primer set having nucleotide sequences as shown in SEQ ID NOs: 55-67, and / or a second single-base extension primer set having nucleotide sequences as shown in SEQ ID NOs: 68-81.
8. The reaction system according to claim 7, characterized in that: The concentration of each amplification primer in the PCR amplification reaction system is 0.5 μM; and / or, The concentrations of the primers in the first single-base extension primer set having nucleotide sequences as shown in SEQ ID NOs: 55-67 are 5.5 μM, 5.5 μM, 8.5 μM, 6.5 μM, 12 μM, 7.5 μM, 10.5 μM, 9 μM, 12 μM, 9.5 μM, 10 μM, 10.5 μM, and 10.5 μM, respectively; The concentrations of each primer in the second single-base extension primer set whose nucleotide sequences are shown in SEQ ID NOs: 68-81 are 6 μM, 37 μM, 12.5 μM, 10 μM, 6 μM, 8 μM, 8.5 μM, 9 μM, 9 μM, 9.5 μM, 9.5 μM, 10 μM, 7.5 μM, and 10.5 μM, respectively.
9. The reaction system according to claim 6, characterized in that: The reaction system also includes one or more of a PCR reaction reagent, a SAP reaction reagent and a single base extension reaction reagent.
10. A venous thromboembolism-related SNP site detection system based on a nucleic acid mass spectrometry platform, characterized in that: The method comprises the reaction system according to any one of claims 6 to 9, and a desalting resin and a spotting chip.
Citation Information
Cited By
Kit for detecting thrombophilia related gene loci on MALDI-TOF (matrix-assisted laser desorption / ionization-time of flight) mass spectrum platform
CN121428082A
Han population venous thromboembolism genetic risk detection primer group, probe group and kit
CN122542673A
